A new drug targeting RAS, a pathologically altered protein causing 40% of colorectal and 90% of pancreatic cancers, has been developed. The molecular eraser, RIBOTAC, stops the production of RAS by degrading its mRNA, but surprisingly triggers changes in cancer cells despite minimal impact on protein quantity.
SourceMax Planck Institute of Molecular Physiology·JournalJACS Au·TypeExperimental study·DateJun 10, 2026
Researchers discovered that brain enzyme OTULIN regulates tau protein accumulation and has implications for treating neurodegenerative diseases. The study revealed OTULIN's role in controlling gene expression and RNA metabolism, suggesting a potential therapeutic target.
SourceGenomic Press·JournalGenomic Psychiatry·TypeExperimental study·DateNov 25, 2025
CalDigit TS4 Thunderbolt 4 Dock
CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.
Researchers have developed a system to selectively switch off the key molecule of NMD, allowing them to observe its function in human cells with unprecedented precision. The study reveals that NMD not only prevents errors but also acts as an important regulator of gene activity.
SourceUniversity of Cologne·JournalMolecular Cell·TypeExperimental study·DateSep 11, 2025
Researchers developed a modified sugar that increases the effectiveness and safety of antisense oligonucleotides, a treatment strategy for central nervous system disease. The modification, called BNAP-AEO, decreases toxic side effects while improving gene silencing in brain cancer cells and mice.
SourceTokyo Medical and Dental University·JournalMolecular Therapy — Nucleic Acids·DateMay 22, 2024
Scientists have discovered an additional source of genetic mutations that cause rare conditions like Huntington's disease. Expanded CAG repeat RNA can form aggregates that reduce global protein synthesis and lead to neurotoxicity.
SourceUniversity of Plymouth·JournalNature Chemical Biology·TypeExperimental study·DateAug 17, 2023
A team of scientists has identified a key player in the coupling between early transcription termination and RNA degradation. The ARS2 protein recruits ZC3H4, which interacts with the NEXT complex to target nascent transcripts for degradation.
SourceAarhus University·JournalMolecular Cell·TypeExperimental study·DateJun 16, 2023
DJI Air 3 (RC-N2)
DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.
Researchers developed a strategy targeting RNA recycling enzymes to prevent harm from cancer genes MYC, JUN and MIR155. This approach showed promise in slowing tumor growth in cancer patients.
SourceUF Health·JournalNature·TypeExperimental study·DateMay 24, 2023
Researchers designed high-fidelity Cas13 variants using mutagenesis to reduce collateral effects, demonstrating their feasibility and efficiency in mammalian cells and animals. The most promising variant, hfCas13d, showed marked reduction in off-target genes and no detectable collateral damage, supporting its potential for gene therapy.
SourceChinese Academy of Sciences Headquarters·JournalNature Biotechnology·DateAug 14, 2022
A new mechanism has been discovered that decorates the end tails of RNA molecules in a parasite causing sleeping sickness, preventing their degradation and potentially increasing virulence. This fundamental discovery opens new avenues for treatment strategies for this disease, as well as other RNA-based infections/diseases.
SourceInstituto de Medicina Molecular·JournalNature·TypeExperimental study·DateMar 30, 2022
McGill researchers uncover a cellular mechanism contributing to communication breakdown between neurons in Alzheimer's disease. They found inadequate levels of the protein RBFOX1, which stabilizes RNAs involved in synaptic transmission, may be a factor in faulty connections characteristic of Alzheimer's.
SourceMcGill University·JournalNature Communications·DateOct 13, 2017